Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Oxford Pharmascience Group (OXP) Share News

Oxford Pharmascience To Start Naproxen Proof-Of-Concept Studies

20th Jan 2015 09:39

Oxford Pharmascience Posts Widened Loss As It Ups Investment

29th Sep 2014 12:08

Oxford Pharmascience Progressing Low Gastric-Irritation Naproxen

15th Sep 2014 10:12

Oxford Pharmascience Agrees Inellare Extension With Brazil's Aché

17th Jun 2014 11:04

LONDON (Alliance News) - Oxford Pharmascience Group PLC Tuesday said it has agreed a line extension with Brazilian pharmaceuticals partner Aché Pharmaceuticos, for a new version of the calcium and vitamin D chew tablet Inellare. The specialty pharmaceutical company said sales of the new ver Read More

Oxford Pharmascience Sees Positive OXP001 Study Results

2nd Jun 2014 10:06

LONDON (Alliance News) - Oxford Pharmascience Group PLC said Monday that it had seen positive results from a pilot clinical study of its reduced gastric irritation ibuprofen product OXP001. The proof of concept clinical study was to determine the extent of upper gastrointestinal irritation Read More

Oxford Pharmascience Appoints Research Firm For Safestat Pilot Study

30th Apr 2014 10:34

LONDON (Alliance News) - Oxford Pharmascience Group PLC said Wednesday it has appointed Quotient Clinical to undertake its early clinical development programme for its OXP003 Safestat product proof of concept study. The specialty pharmaceutical firm said it has appointed the company to unde Read More

DIRECTOR DEALINGS: Oxford Pharmascience Chair Buys 1 Million Shares

26th Mar 2014 10:53

LONDON (Alliance News) - Oxford Pharmascience Group PLC Wednesday said Non-Executive Chairman David Norwood bought 1 million shares at a price of 4.3 pence per share Tuesday. Following this transaction, Norwood now holds 106 million shares, which represents 10.62% stake in the firm. S Read More

Oxford Pharmascience Group Appoints R&D Head

17th Mar 2014 10:54

LONDON (Alliance News) - Oxford Pharmascience Group PLC said Monday it has appointed a Director of research and development to manage the firms' development activities. Dr Liz King has joined to lead and execute the company's development programme focused on the company's two main medicines Read More

Oxford Pharmascience Starts Dosing Subjects In Ibuprofen Study

10th Mar 2014 10:19

LONDON (Alliance News) - Oxford Pharmascience Group PLC Monday said it has begun dosing subjects in the pilot clinical study of its OXP001 400 milligram Ibuprofen treatment. The company redevelops existing medicines to try and make them better, safer and easier to take and is trying to dev Read More

Oxford Pharmascience Pretax Loss Widens, New CEO Appointed

5th Mar 2014 10:39

LONDON (Alliance News) - Oxford Pharmascience Group PLC Wednesday said it appointed a new chief executive and saw a widened pretax loss in 2013 due to increased research and development costs, as it advanced its product programmes towards commercialisation. The pharmaceutical technology com Read More

Oxford Pharmascience Gets Approval For Ibuprofen Product Trial

7th Feb 2014 08:19

LONDON (Alliance News) - Oxford Pharmascience Group PLC Friday said its clinical trial application for OXP001 400 milogram reduced gastric irritation Ibuprofen has received approval from the UK Medicines and Healthcare Products Regulatory Agency and the Ethics Review Committee. The company, Read More

Value8,809.74

Change53.53